Researchers identified PTEN mutations, MAP kinase pathway alterations, and other features linked to anti-PD-1 response in individuals with the brain cancer.
In Nature this week: study of gene drive feasibility in lab mice, circulating tumor DNA from cerebrospinal fluid to track glioma progression, and more.
By profiling the mutation patterns in secondary GBM cases, researchers found recurrent MET alterations and attempted to target it with a MET kinase inhibitor.
Using archived tumor samples from individuals with glioblastoma, researchers saw methylation variability at progression, along with potential prognostic hints.
Researchers uncovered subclones within pediatric glioblastoma and diffuse intrinsic pontine glioma patients that influence the abilities of neighboring cells.
With sequence data for more than 118,000 tumors profiled at Foundation Medicine, investigators tracked PDL1 amplification prevalence and possible treatment implications.